New cancer clinical trial: Randomized, Phase II Trial to Evaluate the Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With Residual Invasive Cancer After Neoadjuvant Chemotherapy

Published on: November 28, 2018 at 12:00PM
Condition:   Triple Negative Breast Cancer
Intervention:   Drug: Atezolizumab
Sponsor:   National Cancer Center, Korea
Not yet recruiting
https://ift.tt/2rd35B0